[January 05, 2016]

Research and Markets: Dementia Associated With Alzheimer's Disease Therapeutics Pipeline Review, H2 2015 - 7 Companies & 10 Drug Profiles

Research and Markets (http://www.researchandmarkets.com/research/vf79df/dementia) has announced the addition of the "Dementia Associated With Alzheimer's Disease - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Dementia Associated With Alzheimer's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

It also reviews key players involved in the theapeutic development for Dementia Associated With Alzheimer's Disease and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

• Adamas Pharmaceuticals, Inc.
• Chase Pharmaceuticals Corporation
• Eisai Co., Ltd.
• FORUM Pharmaceuticals Inc.
• H. Lundbeck A/S
• MediPost Co., Ltd.
• Neurodyn Inc.

Drug Profiles

• memantine hydrochloride ER + donepezil hydrochloride)
• AVCRI-104P3
• CPC (News - Alert)-201
• E-2609
• encenicline hydrochloride
• Gln-1062
• LUAF-20513
• Neurostem
• salicylamine
• TAK-070

For more information visit http://www.researchandmarkets.com/research/vf79df/dementia

View source version on businesswire.com: http://www.businesswire.com/news/home/20160105006256/en/

[ Back To TMCnet.com's Homepage ]